Semaglutide Shows Promise in Treating Heart Failure-Related Symptoms in Both Men and Women

Strategic Insights -

Women with obesity-related heart failure with preserved ejection fraction (HFpEF) experience greater weight reduction with semaglutide compared to men, but both sexes exhibit similar improvements in heart failure-related symptoms, according to a recent study published in the Journal of the American College of Cardiology. The study, which analyzed data from the STEP-HFpEF program, found that semaglutide improved symptoms, physical limitations, and exercise function in both men and women, regardless of the greater weight loss observed in women. The researchers also noted that semaglutide reduced the risk of serious adverse events compared to placebo.

Key Takeaways:

  • Women with obesity-related HFpEF experience significantly greater weight reduction with semaglutide compared to men, with a mean difference of -9.6% in women and -7.2% in men.
  • Both men and women with HFpEF exhibit similar improvements in heart failure-related symptoms with semaglutide, including improvements in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), with mean differences of +7.6 and +7.5, respectively.
  • Semaglutide improved six-minute walk distance (6MWD) and the hierarchical composite end point comprising all-cause death, heart failure events, changes in KCCQ-CSS, and 6MWD in both men and women.
  • The study found that semaglutide reduced the risk of serious adverse events compared to placebo.
  • The researchers also noted that semaglutide reduced inflammation and natriuretic peptides in both men and women.
  • Several authors disclosed ties to biopharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study.
  • The study was conducted as part of the STEP-HFpEF program.

Statistics:

  • Mean body weight reduction in women with HFpEF: -9.6%
  • Mean body weight reduction in men with HFpEF: -7.2%
  • Mean improvement in KCCQ-CSS in women: +7.6
  • Mean improvement in KCCQ-CSS in men: +7.5
  • Mean improvement in 6MWD in women: +14.2 meters
  • Mean improvement in 6MWD in men: +13.5 meters
  • Relative reduction in serious adverse events with semaglutide compared to placebo: 33%

Sources:

  • Journal of the American College of Cardiology, June 23
  • HealthDay News, June 26, 2024
  • American Diabetes Association Annual Meeting, June 21-24, 2024